EMIS
Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ.
Emmis Acquisition Corp. (EMIS) is rated C (2.4/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Momentum (B-); its weakest is Profitability (D). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C+ (2.5) | D (1.5) | B- (2.9) | C+ (2.5) | C (2.4) |
| 2026-11-04 | C+ (2.5) | C+ (2.5) | D (1.5) | B- (2.9) | C+ (2.5) | C (2.4) |
| 2026-10-28 | C+ (2.5) | C+ (2.5) | D (1.5) | C+ (2.8) | C+ (2.5) | C (2.4) |
| 2026-10-21 | C+ (2.5) | C+ (2.5) | D (1.5) | C+ (2.7) | C+ (2.5) | C (2.3) |
| 2026-10-14 | C+ (2.5) | C+ (2.5) | D (1.5) | C+ (2.6) | C+ (2.5) | C (2.3) |